8-K 1 d8k.htm FORM 8-K FOR CORTEX PHARMACEUTICALS Form 8-K for Cortex Pharmaceuticals

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

 

May 10, 2004

 

CORTEX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware    0-17951    33-0303583
(State or other jurisdiction of
incorporation)		    (Commission File Number)    (I.R.S Employer Identification No.)
15241 Barranca Parkway
Irvine, California		    92618
(Address of principal executive offices)    (Zip Code)

 

Registrant’s telephone number, including area code: (949) 727-3157

 

N/A

(Former name or former address, if changed since last report.)

Item 7. Financial Statements and Exhibits.

 

  (a) Financial Statements of Businesses Acquired: None.

 

  (b) Pro Forma Financial Information: None.

 

  (c) Exhibits.

 

Exhibit
Number		    Description
99.1    Press release of Cortex Pharmaceuticals, Inc. dated May 10, 2004.

 

Item 12. Results of Operations and Financial Condition.

 

On May 10, 2004, Cortex Pharmaceuticals, Inc. issued a press release to report its financial results. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

All of the foregoing information, including Exhibit 99.1, is being furnished under Item 12 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

CORTEX PHARMACEUTICALS, INC.

 

Date: May 10, 2004

By:    /s/ Maria S. Messinger

                                                                                                                                                 

Maria S. Messinger

Vice President, Chief Financial Officer

and Corporate Secretary

 

 

2

EXHIBIT INDEX

 

 

Exhibit
Number		    Description    Sequential
Page No.
99.1    Press release of Cortex Pharmaceuticals, Inc. dated May 10, 2004.    4

 

3